NTRK1 and neoplasm: Receptor tyrosine kinase (RTK) inhibitor: Anti-tumor angiogenesis by selectively inhibiting vascular endothelial growth factor receptor-2 (EGFR-2) (Li et al., 2010; Ding et al., 2013).